PENTIXAPHARM HOLDING AG (PTP.DE) Fundamental Analysis & Valuation

FRA:PTP • DE000A40AEG0

Current stock price

2.08 EUR
+0.04 (+1.96%)
Last:

This PTP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. PTP.DE Profitability Analysis

1.1 Basic Checks

  • PTP had negative earnings in the past year.
  • In the past year PTP has reported a negative cash flow from operations.
PTP.DE Yearly Net Income VS EBIT VS OCF VS FCFPTP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2024 0 5M -5M -10M

1.2 Ratios

  • PTP has a Return On Assets of -59.32%. This is amonst the worse of the industry: PTP underperforms 88.89% of its industry peers.
  • With a Return On Equity value of -69.40%, PTP is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -59.32%
ROE -69.4%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTP.DE Yearly ROA, ROE, ROICPTP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2024 0 10 -10 -20

1.3 Margins

  • PTP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTP.DE Yearly Profit, Operating, Gross MarginsPTP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2024 0 100 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. PTP.DE Health Analysis

2.1 Basic Checks

  • PTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for PTP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PTP.DE Yearly Shares OutstandingPTP.DE Yearly Shares OutstandingYearly Shares Outstanding 2024 5M 10M 15M 20M
PTP.DE Yearly Total Debt VS Total AssetsPTP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2024 20M 40M 60M

2.2 Solvency

  • An Altman-Z score of 3.28 indicates that PTP is not in any danger for bankruptcy at the moment.
  • PTP's Altman-Z score of 3.28 is fine compared to the rest of the industry. PTP outperforms 69.84% of its industry peers.
  • PTP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.28
ROIC/WACCN/A
WACC7.45%
PTP.DE Yearly LT Debt VS Equity VS FCFPTP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2024 0 10M 20M 30M 40M

2.3 Liquidity

  • PTP has a Current Ratio of 3.48. This indicates that PTP is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 3.48, PTP belongs to the best of the industry, outperforming 90.48% of the companies in the same industry.
  • A Quick Ratio of 3.48 indicates that PTP has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 3.48, PTP belongs to the best of the industry, outperforming 93.65% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.48
Quick Ratio 3.48
PTP.DE Yearly Current Assets VS Current LiabilitesPTP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. PTP.DE Growth Analysis

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14325%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PTP.DE Yearly Revenue VS EstimatesPTP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2M 4M 6M

More info and screens

Find the best growth stocksShow best growing peers

0

4. PTP.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PTP. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTP.DE Price Earnings VS Forward Price EarningsPTP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTP.DE Per share dataPTP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PTP.DE Dividend Analysis

5.1 Amount

  • No dividends for PTP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PTP.DE Fundamentals: All Metrics, Ratios and Statistics

PENTIXAPHARM HOLDING AG

FRA:PTP (4/14/2026, 7:00:00 PM)

2.08

+0.04 (+1.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners4.34%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap51.58M
Revenue(TTM)6.93M
Net Income(TTM)-25.48M
Analysts80
Price Target11.95 (474.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.44
P/FCF N/A
P/OCF N/A
P/B 1.4
P/tB 14.63
EV/EBITDA N/A
EPS(TTM)-0.86
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0.28
BVpS1.48
TBVpS0.14
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -59.32%
ROE -69.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.48
Quick Ratio 3.48
Altman-Z 3.28
F-ScoreN/A
WACC7.45%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14325%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

PENTIXAPHARM HOLDING AG / PTP.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PENTIXAPHARM HOLDING AG (PTP.DE) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PTP.DE.


What is the valuation status of PENTIXAPHARM HOLDING AG (PTP.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to PENTIXAPHARM HOLDING AG (PTP.DE). This can be considered as Overvalued.


Can you provide the profitability details for PENTIXAPHARM HOLDING AG?

PENTIXAPHARM HOLDING AG (PTP.DE) has a profitability rating of 0 / 10.